| P50 | author | Guenther Hochhaus | Q55427575 |
| P2093 | author name string | Mong-Jen Chen | |
| | Renishkumar Delvadia | |
| | Bhawana Saluja | |
| | Mohammad Absar | |
| | Xiangyin Wei | |
| | Sharvari Bhagwat | |
| | Uta Schilling | |
| P2860 | cites work | Venous thromboembolism and lung cancer: a review | Q26784184 |
| | Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler | Q28365894 |
| | A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System | Q29042157 |
| | Modeling and comparison of dissolution profiles | Q34215811 |
| | Dry powder inhalers and the right things to remember: a concept review | Q35426748 |
| | Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. | Q35825280 |
| | Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method | Q35826707 |
| | Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers | Q35896882 |
| | Solubility Enhancement of Budesonide and Statistical Optimization of Coating Variables for Targeted Drug Delivery | Q36112246 |
| | In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing | Q37365183 |
| | Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product | Q38185862 |
| | Inhaled corticosteroids: potency, dose equivalence and therapeutic index | Q38390724 |
| | Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition | Q39291826 |
| | Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs | Q40258577 |
| | A pharmacokinetic simulation tool for inhaled corticosteroids. | Q42507245 |
| | Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate | Q42678294 |
| | Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects | Q43836979 |
| | Transport and deposition of micro-aerosols in realistic and simplified models of the oral airway. | Q44926315 |
| | In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans | Q44970565 |
| | Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration | Q46700775 |
| | Fast calculation of van der Waals volume as a sum of atomic and bond contributions and its application to drug compounds | Q47632144 |
| | Normal organ weights in men: part II-the brain, lungs, liver, spleen, and kidneys | Q48766796 |
| | An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects | Q50247636 |
| | Dissolution testing of powders for inhalation: influence of particle deposition and modeling of dissolution profiles. | Q51083967 |
| | Evaluation of the Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane and Surfactant. | Q51620315 |
| | Models of human lung airways and their application to inhaled particle deposition. | Q52767790 |
| | New Method for Calculating the Intrinsic Absorption Rate of Drugs | Q53021749 |
| | Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution | Q68861405 |
| | Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI | Q72426713 |
| | Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers | Q73181965 |
| | Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers | Q73350559 |
| | Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model | Q74321636 |
| | Dissolution rates of finely divided drug powders. II. Micronized methyl-prednisolone | Q79523075 |
| | Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products | Q86165264 |
| P433 | issue | 12 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 2541-2556 | |
| P577 | publication date | 2017-08-10 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers | |
| P478 | volume | 34 | |